Key eligibility criteria for both trials included adults or adolescents with a diagnosis of AD as defined by the AAD consensus criteria, for at least 1 year prior to screening.
Patients treated with rocatinlimab had progressive improvements in atopic dermatitis,
which was maintained in most patients after treatment discontinuation. Treatment was
well tolerated.